{"id":8733,"date":"2026-01-20T13:24:55","date_gmt":"2026-01-20T13:24:55","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8733"},"modified":"2026-01-20T13:24:55","modified_gmt":"2026-01-20T13:24:55","slug":"gsk-to-acquire-rapt-therapeutics-for-2-2-billion-strengthening-its-immunology-pipeline","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/01\/20\/gsk-to-acquire-rapt-therapeutics-for-2-2-billion-strengthening-its-immunology-pipeline\/","title":{"rendered":"GSK to Acquire RAPT Therapeutics for $2.2 Billion, Strengthening Its Immunology Pipeline"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Deal delivers global rights to experimental food allergy therapy ozureprubart as GSK pursues growth under new CEO Luke Miels.<\/em><\/h4>\n\n\n\n<p>Britain\u2019s <strong>GSK<\/strong> announced it will acquire <strong>RAPT Therapeutics<\/strong> for <strong>$2.2 billion<\/strong>, marking the first major acquisition under newly appointed CEO <strong>Luke Miels<\/strong>. The deal adds global rights to RAPT\u2019s experimental food allergy treatment <strong>ozureprubart<\/strong>, positioning it as a strategic expansion of GSK\u2019s respiratory and immunology portfolio as the company looks to offset looming revenue pressure from patent expirations.<\/p>\n\n\n\n<p>Under the terms, GSK will pay <strong>$58 per share<\/strong> for RAPT, including an upfront investment of <strong>$1.9 billion<\/strong>. The acquisition provides GSK global rights to ozureprubart <strong>excluding mainland China, Macau, Taiwan, and Hong Kong<\/strong>. Investors quickly responded to the announcement, sending RAPT shares sharply higher in premarket trading, while GSK\u2019s shares dipped modestly as the market assessed the price and strategic impact.<\/p>\n\n\n\n<p>Ozureprubart is designed to reduce inflammation triggered by allergic reactions by targeting an antibody involved in the immune response. Importantly, the therapy may offer <strong>less frequent dosing<\/strong> than current standards of care, a potential advantage in a market where convenience, compliance, and safety are critical factors. GSK\u2019s Chief Scientific Officer Tony Wood said the acquisition aligns with the company\u2019s strategy of pursuing assets aimed at validated targets with clear unmet medical needs.<\/p>\n\n\n\n<p>The acquisition comes as GSK navigates a shifting global landscape, including concerns around U.S. tariffs, while seeking new growth drivers to meet its long-term goals. Investors are closely watching Miels\u2019 leadership as the company targets <strong>more than \u00a340 billion ($54 billion) in annual revenue by 2031<\/strong>.<\/p>\n\n\n\n<p>In a separate development, GSK also announced that Japan\u2019s <strong>Shionogi<\/strong> will increase its stake in <strong>ViiV Healthcare<\/strong>, following Pfizer\u2019s exit from the HIV-focused joint venture. GSK will retain its majority <strong>78.3% stake<\/strong> and receive a <strong>$250 million special dividend<\/strong> as ViiV cancels Pfizer\u2019s shares.<\/p>\n\n\n\n<p>Together, the moves signal a more aggressive, pipeline-focused strategy as GSK positions itself for the next decade of growth.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/15\/callan-jmb-and-attune-biotech-form-strategic-alliance-to-accelerate-federal-medical-deployments\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Callan JMB and Attune Biotech Form Strategic Alliance to Accelerate Federal Medical Deployments<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Deal delivers global rights to experimental food allergy therapy ozureprubart as GSK pursues growth under new CEO Luke Miels. Britain\u2019s GSK announced it will acquire RAPT Therapeutics for $2.2 billion, marking the first major acquisition under newly appointed CEO Luke Miels. The deal adds global rights to RAPT\u2019s experimental food allergy treatment ozureprubart, positioning it [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1142,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,361],"tags":[421,894,460,416,418,895,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8733"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8733"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8733\/revisions"}],"predecessor-version":[{"id":8734,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8733\/revisions\/8734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1142"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8733"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}